Literature DB >> 32101469

Development of a Composite Primary Outcome Score for Children with Attention-Deficit/Hyperactivity Disorder and Emotional Dysregulation.

Jeanette M Johnstone1,2, Brenda M Y Leung3, Priya Srikanth4, Irene Hatsu5, Leanna Perez5, Barbara Gracious6,7, Gabriella Tost2, Michael G Aman8, Kenneth D Gadow9, Robert L Findling10, Oscar Bukstein11, L Eugene Arnold6.   

Abstract

Objective: Study goals were to (1) provide a rationale for developing a composite primary outcome score that includes symptom severity for attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation, plus symptom-induced impairment; (2) demonstrate weighting methods to calculate the composite score using a sample of children diagnosed with ADHD and aggression; and (3) identify the optimal weighting method most sensitive to change, as measured by effect sizes.
Methods: We conducted secondary data analyses from the previously conducted Treatment of Severe Childhood Aggression (TOSCA) study. Children aged 6-12 years were recruited through academic medical centers or community referrals. The composite primary outcome comprised the ADHD, oppositional defiant disorder, disruptive mood dysregulation disorder, and peer conflict subscales from the Child and Adolescent Symptom Inventory (CASI), a DSM (Diagnostic and Statistical Manual)-referenced rating scale of symptom severity and symptom-induced impairment. Five weighting methods were tested based on input from senior statisticians.
Results: The composite score demonstrated a larger (Cohen's d) effect size than the individual CASI subscales, irrespective of the weighting method (10%-55% larger). Across all weighting methods, effect sizes were similar and substantial: approximately a two-standard deviation symptom reduction (range: -1.97 to -2.04), highest for equal item and equal subscale weighting, was demonstrated, from baseline to week 9, among all TOSCA participants. The composite score showed a medium positive correlation with the Clinical Global Impressions-Severity scores, 0.46-0.47 for all weighting methods. Conclusions: A composite score that included severity and impairment ratings of ADHD and emotional dysregulation demonstrated a more robust pre-post change than individual subscales. This composite may be a more useful indicator of clinically relevant improvement in heterogeneous samples with ADHD than single subscales, avoiding some of the statistical limitations associated with multiple comparisons. Among the five similar weighting methods, the two best appear to be the equal item and equal subscale weighting methods.

Entities:  

Keywords:  ADHD; aggression; composite primary outcome; emotional dysregulation; irritability; symptom severity and impairment

Mesh:

Year:  2020        PMID: 32101469      PMCID: PMC7153642          DOI: 10.1089/cap.2019.0179

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  24 in total

1.  Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.

Authors:  Kenneth D Gadow; L Eugene Arnold; Brooke S G Molina; Robert L Findling; Oscar G Bukstein; Nicole V Brown; Nora K McNamara; E Victoria Rundberg-Rivera; Xiaobai Li; Heidi L Kipp; Jayne Schneider; Cristan A Farmer; Jennifer L Baker; Joyce Sprafkin; Robert R Rice; Srihari S Bangalore; Eric M Butter; Kristin A Buchan-Page; Elizabeth A Hurt; Adrienne B Austin; Sabrina N Grondhuis; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-06-12       Impact factor: 8.829

Review 2.  Pharmacotherapy of emotional dysregulation in adults with ADHD: A systematic review and meta-analysis.

Authors:  Francesca Lenzi; Samuele Cortese; Joseph Harris; Gabriele Masi
Journal:  Neurosci Biobehav Rev       Date:  2017-08-26       Impact factor: 8.989

Review 3.  Emotion dysregulation in attention deficit hyperactivity disorder.

Authors:  Philip Shaw; Argyris Stringaris; Joel Nigg; Ellen Leibenluft
Journal:  Am J Psychiatry       Date:  2014-03       Impact factor: 18.112

4.  Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment.

Authors:  J M Swanson; H C Kraemer; S P Hinshaw; L E Arnold; C K Conners; H B Abikoff; W Clevenger; M Davies; G R Elliott; L L Greenhill; L Hechtman; B Hoza; P S Jensen; J S March; J H Newcorn; E B Owens; W E Pelham; E Schiller; J B Severe; S Simpson; B Vitiello; K Wells; T Wigal; M Wu
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

5.  A systematic evaluation of ADHD and comorbid psychopathology in a population-based twin sample.

Authors:  Heather E Volk; Rosalind J Neuman; Richard D Todd
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2005-08       Impact factor: 8.829

6.  Relation of symptom-induced impairment with other illness parameters in clinic-referred youth.

Authors:  Kenneth D Gadow; Aaron J Kaat; Luc Lecavalier
Journal:  J Child Psychol Psychiatry       Date:  2013-04-16       Impact factor: 8.982

7.  Psychiatric symptom impairment in children with autism spectrum disorders.

Authors:  Aaron J Kaat; Kenneth D Gadow; Luc Lecavalier
Journal:  J Abnorm Child Psychol       Date:  2013-08

8.  Subtyping attention-deficit/hyperactivity disorder using temperament dimensions: toward biologically based nosologic criteria.

Authors:  Sarah L Karalunas; Damien Fair; Erica D Musser; Kamari Aykes; Swathi P Iyer; Joel T Nigg
Journal:  JAMA Psychiatry       Date:  2014-09       Impact factor: 21.596

9.  Categorical and Dimensional Definitions and Evaluations of Symptoms of ADHD: History of the SNAP and the SWAN Rating Scales.

Authors:  James M Swanson; Sabrina Schuck; Miranda Mann Porter; Caryn Carlson; Catharina A Hartman; Joseph A Sergeant; Walter Clevenger; Michael Wasdell; Richard McCleary; Kimberley Lakes; Timothy Wigal
Journal:  Int J Educ Psychol Assess       Date:  2012-04

10.  Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA).

Authors:  Lorena Fernández de la Cruz; Emily Simonoff; James J McGough; Jeffrey M Halperin; L Eugene Arnold; Argyris Stringaris
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2014-10-18       Impact factor: 8.829

View more
  4 in total

Review 1.  Diagnostic instruments for the assessment of disruptive mood dysregulation disorder: a systematic review of the literature.

Authors:  Ines Mürner-Lavanchy; Michael Kaess; Julian Koenig
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-07-07       Impact factor: 4.785

2.  Pain sensitivity and perceptual sensitivity are associated with severity of emotional dysregulation in children with ADHD: a cross-sectional analysis using the Temperament in Middle Childhood Questionnaire.

Authors:  Alisha M Bruton; Angela Senders; Gabriella Tost; Hayleigh Ast; Lisa M Robinette; Brenda Leung; Irene E Hatsu; L Eugene Arnold; Jeanette M Johnstone
Journal:  Disabil Rehabil       Date:  2022-03-10       Impact factor: 2.439

3.  Micronutrients for Attention-Deficit/Hyperactivity Disorder in Youths: A Placebo-Controlled Randomized Clinical Trial.

Authors:  Jeanette M Johnstone; Irene Hatsu; Gabriella Tost; Priya Srikanth; Leanna P Eiterman; Alisha M Bruton; Hayleigh K Ast; Lisa M Robinette; Madeline M Stern; Elizabeth G Millington; Barbara L Gracious; Andrew J Hughes; Brenda M Y Leung; L Eugene Arnold
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2021-07-22       Impact factor: 13.113

4.  A two arm randomized controlled trial comparing the short and long term effects of an elimination diet and a healthy diet in children with ADHD (TRACE study). Rationale, study design and methods.

Authors:  Annick Bosch; Margreet Bierens; Ardine G de Wit; Verena Ly; Jessica van der Velde; Heleen de Boer; Gerry van Beek; Danielle Appelman; Sacha Visser; Lisa Bos; Jolanda van der Meer; Niki Kamphuis; Jos M T Draaisma; Rogier Donders; Gigi H H van de Loo-Neus; Pieter J Hoekstra; Marco Bottelier; Alejandro Arias-Vasquez; Helen Klip; Jan K Buitelaar; Saskia W van den Berg; Nanda N Rommelse
Journal:  BMC Psychiatry       Date:  2020-05-27       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.